CSColin A. Sieff

Colin A. Sieff

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Colin A. Sieff has a total of 17 co-authors. Here are the top co-authors by number of shared publications:

  • Aravind Subramanian

    From the Departments of Medical Oncology and Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and the Broad Institute of Harvard and Massachusetts Institute of Technology (MIT), Cambridge, MA

    1 shared publication
  • Benjamin L. Ebert

    Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA

    1 shared publication
  • Bernard Mathey-Prevot

    Department of Pediatrics, Harvard Medical School, The Children's Hospital and Dana Farber Cancer Institute, Boston, USA

    1 shared publication
  • Charlotte M Niemeyer

    Department of Pediatrics, Harvard Medical School, The Children's Hospital and Dana Farber Cancer Institute, Boston, USA

    1 shared publication
  • David G Nathan

    Department of Pediatrics, Harvard Medical School, The Children's Hospital and Dana Farber Cancer Institute, Boston, USA

    1 shared publication
  • David G. Nathan

    1 shared publication

Latest Publications

  • An RNA interference model of RPS19 deficiency in Diamond-Blackfan anemia recapitulates defective hematopoiesis and rescue by dexamethasone: identification of dexamethasone-responsive genes by microarray

    by Benjamin L. Ebert, Michele M. Lee, Jennifer L. Pretz, Aravind Subramanian, Raymond Mak, Todd R. Golub, Colin A. Sieff

    Diamond-Blackfan anemia (DBA), a congenital erythroblastopenia, is a model disease for the study of erythroid differentiation but is poorly understood. RPS19 is the only gene yet to have been associated with DBA, but its relevance to erythroid differentiation is unclear. The molecular basis for the stimulation of erythropoiesis by glucocorticoids in patients with DBA has not been identified. We demonstrate that targeted degradation of the RPS19 transcript, through retroviral expression of short hairpin RNAs (shRNAs), blocks the proliferation and differentiation of erythroid progenitor cells in cultured human CD34+ cells. Treatment of RPS19-deficient cells with dexamethasone restores erythroid differentiation to normal levels. We investigated the molecular basis of pharmacologic therapies for DBA using oligonucleotide microarrays to survey gene expression in CD34+ cells treated with combinations of dexamethasone, erythropoietin, stem cell factor, and interleukin-3. Dexamethasone did not alter expression of RPS19 but activated a genetic program that includes a set of key hematopoietic regulatory genes. Genes specific to erythroid progenitor cells were up-regulated by dexamethasone, while genes specific to nonerythroid lineages were down-regulated. Deficiency of RPS19 therefore blocks proliferation of immature erythroid progenitor cells, and dexamethasone activates proliferation of the same cell population through mechanisms independent of RPS19. (Blood. 2005;105:4620-4626)


  • Congenital bone marrow failure syndromes

    by Colin A. Sieff, Eric Nisbet-Brown, David G. Nathan


  • Maturation and Lineage‐Specific Expression of the Coxsackie and Adenovirus Receptor in Hematopoietic Cells

    by Vivienne I. Rebel, Sheila Hartnett, Jessica Denham, Melvin Chan, Robert Finberg, Colin A. Sieff

    Adenovirus vectors have been used to transfer genes into both hematopoietic progenitor cells and tumor cells, including carcinoma cells that have metastasized to bone marrow (BM). However, the relative susceptibility of different subsets of hematopoietic cells is unknown. In permissive cells adenoviral-mediated gene transfer is mediated by the coxsackievirus and adenovirus receptor (CAR) protein and alpha(v) integrins expressed on the cell surface of the target cells. This prompted us to investigate the expression of CAR on subpopulations of hematopoietic cells, determine whether this protein played a role in adenovirus-mediated gene transfer of hematopoietic cells and whether we could modulate CAR to enhance gene transfer efficiency. In this report we show that CAR is expressed on approximately 40% of all human BM cells, including erythroid and myeloid cells, but not lymphoid cells. Of the CD34(+) cells, 10%-15% expressed CAR, but this did not include most colony-forming progenitor cells, nor the most primitive CD38(-) subpopulation. The presence of CAR correlated well with gene transfer efficiency, but we were unable to induce CAR expression on immature, noncommitted progenitor cells. In conclusion, our results show that primitive hematopoietic progenitor cells lack CAR expression, but that expression is acquired during erythroid and myeloid differentiation.


  • THE REGULATION OF HUMAN ERYTHROPOIESIS BY GROWTH FACTORS

    by David G Nathan, Bernard Mathey-Prevot, Charlotte M Niemeyer, Jennifer Z Wlmperls, Colin A Sieff